Consistent with previous studies of Gls1 or BPTES in autoimmune disorders, we suggest that further clinical trials or biological safety analyses are recommended for the drug design of BPTES as a Gls1 inhibitor. The gene discussed is GLS; the disease is autoimmune disease.